IPF Weekly Update
ChatGPTなどを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
24/10/04
[PDF] Pirfenidone as a Cornerstone in the Management of Fibrotic Interstitial Lung Diseases and Its Emerging Applications: A Comprehensive Review
H Babariya, SA Gaidhane, S Acharya, S Kumar… - Cureus, 2024
… These diseases include idiopathicpulmonary fibrosis (IPF), connective tissue disease-associated ILD (CTD-ILD), and chronic hypersensitivity pneumonitis (CHP), among others [2]. Despite their differing etiologies, these conditions share a …
- 線維性間質性肺疾患の治療における基礎としてのピルフェニドンとその新たな応用：包括的レビュー
24/10/03
[PDF] Recent insights into the role of antifibrotic drugs in the management of idiopathic pulmonary fibrosis (IPF)
R Chakraverty, J Bondyopadhyay
… Idiopathic aspiratory fibrosis (IPF) is the most well-known sort of idiopathic interstitial pneumonia (IIP). IIPs are precipitously shappening (idiopathic) diffuse parenchymal lung illnesses. IPF is characterized as a precipitouly happening (idiopathic) …
- 特発性肺線維症（IPF）の管理における抗線維化薬の役割に関する最近の知見
[HTML] Health-related quality of life measured with K-BILD is associated with survival in patients with idiopathic pulmonary fibrosis
T Rautajoki, HA Rantala, E Sutinen, T Saarto, K Rajala… - BMC Pulmonary Medicine, 2024
… ) assessments and estimates of prognosis are needed for comprehensive care and planning of subsequent treatment in patients with idiopathicpulmonary fibrosis (IPF). We investigated HRQoL and its association with survival using a disease-specific …
- K-BILDで測定された健康関連の生活の質は、特発性肺線維症患者の生存率と関連している
[HTML] Anti-interferon gamma-inducible protein 16 antibodies: Identification of a novel autoantigen in idiopathic interstitial pneumonia and its clinical characteristics based on …
T Sasai, R Nakashima, T Handa, Y Yamano, Y Kondo… - Clinical Immunology, 2024
Autoantibodies are detected in idiopathicinterstitial pneumonias (IIPs) without a clear connective tissue disease diagnosis, and their clinical significance is unclear. This study aimed to identify a novel autoantibody in IIPs. We screened 295 IIP …
Revisiting the Role of MicroRNAs in the Pathogenesis of Idiopathic Pulmonary Fibrosis
Z Zhou, Y Xie, Q Wei, Z Xu - Frontiers in Cell and Developmental Biology
… the epidemiology of IPF, discusses the multifaceted regulatory roles of miRNAs in IPF, and explores the impact of miRNAs on IPFthrough various … Consequently, we investigate the potential for targeting miRNAs as a treatment for IPF, thereby …
- 特発性肺線維症の発症におけるマイクロRNAの役割の再検討
Regenerative capacity of alveolar type 2 cells is proportionally reduced following disease progression in idiopathic pulmonary fibrosis-derived organoid cultures
HK Choi, G Bang, JH Shin, MH Shin, A Woo, SY Kim… - Tuberculosis and respiratory …
… central role in IPF pathophysiology. Purpose: This study aimed to investigate the regenerative capacity of AT2 cells using IPF-derived alveolar … Conclusion: This study confirmed that the regenerative capacity of AT2 cells in IPFdecreases as the …
- 特発性肺線維症由来オルガノイド培養における肺胞2型細胞の再生能力は、疾患の進行に伴って比例して低下する
Variability in Chest Radiology Interpretation between Thoracic and Non-Thoracic Radiologists: Implications for Pulmonary Fibrosis Care
DM Guidot, D Seaman, RA Pleasants, A Bedoya… - Respiratory Medicine, 2024
… Idiopathic pulmonary fibrosis (IPF) is a severe disease of progressive lung scarring with a median survival of 3.8 years. Current therapeutics slow disease progression but do not reverse existing fibrosis. Thus, timely diagnosis is crucial to …
INVESTIGATING MACROPHAGES AND MONOCYTES AS PROFIBROTIC IMMUNOPATHOGENIC CONTRIBUTORS TO PULMONARY FIBROSIS
M Vierhout - 2024
… Abstract: Idiopathic pulmonary fibrosis(IPF) is a fatal and relentless form of interstitial lung disease, characterized by excessive … of IPF is relatively poor and comparable to some aggressive forms of cancer, with a median survival of just 3 to 5 …
- 肺線維症の線維化促進免疫病原性因子としてのマクロファージと単球の調査
Alveolar type 2 cells marker gene SFTPC inhibits epithelial-to-mesenchymal transition by upregulating SOX7 and suppressing WNT/β-catenin pathway in non-small …
Q Zhang, N An, Y Liu, Y Zhu, W Pan, P Gu, J Zhao… - Frontiers in oncology, 2024
… Mutations or deletions in SFTPC cause idiopathic pulmonary fibrosis (IPF). Importantly, IPF is an independent risk factor for non-small cell lung cancer (NSCLC). It suggests that abnormal expression of SFTPC may be relevant to development of …
- 肺胞2型細胞マーカー遺伝子SFTPCは、非小細胞肺癌においてSOX7をアップレギュレーションし、WNT/β-カテニン経路を抑制することで上皮間葉転換を阻害する
24/10/02
[HTML] Asymptomatic thrombocytopenia after nintedanib initiation in a patient with progressive pulmonary fibrosis: a case report and review of literature
X Zhang, K Zhang, N Zhao, N Xi, T Zhao - Journal of Medical Case Reports, 2024
… It has noteworthy antifibrotic property and has been approved for treating idiopathicpulmonary fibrosis (IPF), systemic sclerosis-interstitial lung disease (SSc-ILD), and progressive pulmonary fibrosis (PPF). In addition to its antifibrotic effects …
- 進行性肺線維症患者におけるニンテダニブ投与開始後の無症候性血小板減少症：症例報告と文献レビュー
24/10/01
[HTML] CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort study
N Enomoto, S Nakai, S Yazawa, Y Mochizuka… - Respiratory Research, 2024
… disease (CTD-ILD) is the second highest after those with idiopathic interstitial pneumonias (IIP), especially idiopathic pulmonary fibrosis(IPF) [1]. The most important differences between CTD-ILD and IPF are the treatment response and …
[HTML] Acute exacerbation of interstitial lung disease after transthoracic biopsy
FM Costa, MT Cerezoli, C Shiang, BL Moreira… - Jornal Brasileiro de …, 2024
… with idiopathic pulmonary fibrosis. … idiopathic pulmonary fibrosis. For the treatment of AE-ILD, the recommendation in the literature is to use a high dose of methylprednisolone (500-1000 mg per day) for three days. 8 Kim DS. Acute …
- 経胸壁生検後の間質性肺疾患の急性増悪
24/09/30
[HTML] Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
VK Viswanathan, AG Ghoshal, A Mohan, K Patil… - Pulmonary Therapy, 2024
… This review discusses the underlying physiological processes of IPF and the mechanism of action of nintedanib in IPF. It evaluates the effectiveness and tolerability of nintedanib in patients with IPF, with a particular focus on patient …
- 特発性肺線維症患者におけるニンテダニブを用いた患者プロファイルに基づく管理
[HTML] Identification of immune patterns in idiopathic pulmonary fibrosis patients driven by PLA2G7-positive macrophages using an integrated machine learning survival …
T Liu, J Ning, X Fan, H Wei, G Shi, QB Fu - Scientific Reports, 2024
… Idiopathic pulmonary fibrosis (IPF) is a complex and incurable pulmonary disease with an elusive etiology 1 . Its prevalence varies, affecting 20–80 individuals per 100,000, with a notable predominance in males with a history of cigarette smoking 2 …
Lung-Targeting Perylenediimide Nanocomposites for Efficient Therapy of Idiopathic Pulmonary Fibrosis
Y Liu, D Xu, X Xing, A Shen, X Jin, S Li, Z Liu, L Wang… - Nano Letters, 2024
… Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal respiratory lung diseases that highly associated with dysfunction of fibroblasts … among IPF patients underscores the need for improved therapeutic options. Based on reported data …
- 特発性肺線維症の効果的な治療のための肺を標的とするペリレンジイミドナノ複合材料
[PDF] Integrating cellular experiments, single-cell sequencing, and machine learning to identify endoplasmic reticulum stress biomarkers in idiopathic pulmonary fibrosis
Y Liao, X Peng, Y Yang, G Zhou, L Chen, Y Yang, H Li… - Annals of Medicine, 2024
… Idiopathic Pulmonary Fibrosis (IPF) presents a severe respiratory challenge with a poor prognosis due to the lack of reliable biomarkers. … Reticulum Stress (ERS) may be associated with IPF pathogenesis. This study focuses on uncovering ERS-associated …
- 細胞実験、単一細胞シーケンシング、機械学習を統合し、特発性肺線維症における小胞体ストレスバイオマーカーを特定する
[HTML] Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis
LJ Lobo, Y Liu, P Li, M Ramaswamy, AC Swaminathan… - BMC Pulmonary Medicine, 2024
… This registry is enrolling patients with an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis who have reticular abnormality … Idiopathic pulmonaryfibrosis (IPF) is a type of ILD that is always associated with progressive …
- 進行性肺線維症患者におけるILD-PROレジストリの設計とベースライン特性
GTSE1-driven ZEB1 Stabilization Promotes Pulmonary Fibrosis Through the Epithelial-to-mesenchymal Transition
H Jin, SY Park, JE Lee, H Park, M Jeong, H Lee, J Cho… - Molecular Therapy, 2024
… Here, we explored the genomic data of patients with idiopathic PF (IPF) and found that GTSE1 expression is elevated in their lung tissues, … using IPF patient tissues and PF mouse models. The comprehensive bioinformatics analyses suggested that …
- GTSE1 による ZEB1 の安定化は上皮間葉転換を通じて肺線維症を促進する
[HTML] Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index
H Li, X Fu, M Liu, J Chen, W Cao, Z Liang, ZJ Cheng… - BMC Cancer, 2024
… pulmonary fibrosis (PF) and interstitial lung disease (ILD) contribute to an intricate landscape of respiratory diseases. Idiopathic pulmonaryfibrosis (IPF… Interstitial lung diseases (ILD) — which include a wide variety of conditions, among them …
- 血液学的指標に基づく肺線維症を伴う肺腺癌の早期スクリーニングの新しい予測モデル
[PDF] Pirfenidone in the Treatment of Radiation-Induced Lung Injury: A Randomized, Controlled, Multicenter Clinical Trial
M Chen, Z Hou, Q Yao, H Chen, Q Shao, M LI, J Wang… - International Journal of …, 2024
… Pirfenidone is indicated for idiopathicpulmonary fibrosis, and our experiments have shown that it ameliorates alveolar inflammation and fibrosis in mice after radiation, and its mechanism of action is similar to the pathophysiological process of …
24/09/29
[HTML] MICROSCOPIC POLYANGIITIS PRESENTING AS IDIOPATHIC PULMONARY FIBROSIS
B Duchene - Respiratory Medicine Case Reports, 2024
… with pulmonary fibrosis. In some cases, ILD (interstitial lung disease) is the initial clinical manifestation of MPA (22% of cases). Here, we describe a patient diagnosed with IPF(idiopathic pulmonary fibrosis… of suspected IPF, which may result in more …
- 特発性肺線維症として現れる顕微鏡的多発血管炎
[HTML] Trigonelline mitigates bleomycin-induced idiopathic pulmonary fibrosis in mice
S Gavhane, C Gawli, S Kumar, B Das, G Marathe… - Asian Pacific Journal of …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease … , and protein targets and molecular pathways of idiopathic pulmonary fibrosis. The green circle on the … shared between bleomycin and trigonelline in …
- トリゴネリンはマウスにおけるブレオマイシン誘発性特発性肺線維症を軽減する
[HTML] Optimization and Appraisal of Nintedanib-Loaded Mixed Polymeric Micelles as a Potential Nanovector for Non-Invasive Pulmonary Fibrosis Mitigation
HM Aboud, SF El Menshawe, NH Mohammed… - Pharmaceuticals, 2024
… Idiopathic pulmonary fibrosis (IPF) is an uncommon and progressive chronic lung disease characterized by unknown causes, leading to mental and physical distresses [2]. A significant fraction of the global yearly mortality rate is attributable to …
[HTML] Diagnostic value of Krebs von den Lungen-6, a serological biomarker in interstitial lung disease
C Navya, P Radhakrishnan, S Yuvarajan, R Mohan - Journal of Current Research in …
… Among the 56 study participants, the subtypes of ILD include idiopathic pulmonary fibrosis(IPF) in connective tissue disorder (CTD)-ILD and others with a frequency of 23.18 and 15, respectively. The mean age of the study participants was …
- 間質性肺疾患における血清学的バイオマーカー、Krebs von den Lungen-6 の診断的価値
[HTML] Collaborative effort reduces COPD readmissions, costs
N Osterweil
… At that time, it was already a known genetic risk factor for idiopathic pulmonary fibrosis in the general population. The new data confirm the … At that time, it was already a known genetic risk factor for idiopathic pulmonary fibrosis in the general …
- 協力的な取り組みによりCOPDの再入院とコストが減少
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
